| 引用本文: |
李方芳, 陈雄, 汤钰, 喻娟, 彭俊, 彭清华, 姚小磊.散血明目片联合康柏西普治疗糖尿病性黄斑水肿的临床观察[J].湖南中医药大学学报,2025,45(9):1758-1763[点击复制] |
|
| |
|
|
| 本文已被：浏览 1478次 下载 725次 |
| 散血明目片联合康柏西普治疗糖尿病性黄斑水肿的临床观察 |
| 李方芳,陈雄,汤钰,喻娟,彭俊,彭清华,姚小磊 |
| (湖南中医药大学, 湖南 长沙 410208;湖南中医药大学第一附属医院, 湖南 长沙 410007;东莞市清溪医院, 广东 东莞 523641;中医药防治眼耳鼻咽喉疾病湖南省重点实验室, 湖南 长沙 410208) |
| 摘要: |
| 目的 探讨散血明目片与康柏西普联合使用治疗糖尿病性黄斑水肿（DME）的临床疗效。方法 纳入2021年1月至2022年1月于湖南中医药大学第一附属医院眼科就诊的DME患者45例（共45眼），采用随机数字表法分为试验组和对照组，其中：试验组22例（共22眼），均使用散血明目片和康柏西普联合治疗；对照组23例（共23眼），皆使用康柏西普治疗。治疗后，检测两组患者的最佳矫正视力（BCVA）、黄斑部中心凹视网膜厚度（CMT），并比较临床疗效和不良反应发生情况。结果 与治疗前相比，两组患者治疗后1 d及治疗后1、2、3个月BCVA logMAR值均降低（P<0.05）；进一步两两比较发现，试验组、对照组在治疗后1、2、3个月BCVA logMAR值均较前一个时间点降低（P<0.05）；与对照组相比，试验组在治疗后1、2、3个月BCVA logMAR值均降低（P<0.05）。与治疗前相比，两组患者治疗后1、2、3个月CMT均降低（P<0.05）；进一步两两比较发现，试验组、对照组在治疗后1、2、3个月CMT均较前一个时间点降低（P<0.05）；与对照组相比，试验组在治疗后1、2、3个月CMT均降低（P<0.05）。试验组临床总有效率高于对照组（P<0.05），两组患者均未发生不良反应。结论 散血明目片和康柏西普均可有效提高DME患者视力、降低CMT，而二者联合使用效果更显著。 |
| 关键词: 糖尿病性黄斑水肿 散血明目片 康柏西普 最佳矫正视力 黄斑部中心凹视网膜厚度 临床疗效 |
| DOI：10.3969/j.issn.1674-070X.2025.09.024 |
| 投稿时间：2025-02-17 |
| 基金项目:湖南中医药大学“揭榜挂帅”项目(22JBZ029); 湖南省重点研发计划项目(2024JK2122); 湖南省中医药科技计划重点项目(A2023001); 湖南省科技厅临床引导项目(2021SK51402); 湖南省教育厅“芙蓉学者·青年学者”(湘人才办发[2022]3号); 湖南省卫生健康高层次人才医学学科带头人(2023年)。 |
|
| Clinical observation on the treatment of diabetic macular edema with Sanxue Mingmu Tablet combined with Conbercept |
| LI Fangfang, CHEN Xiong, TANG Yu, YU Juan, PENG Jun, PENG Qinghua, YAO Xiaolei |
| (Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China;Dongguan Qingxi Hospital, Dongguan, Guangdong 523641, China;Hunan Key Laboratory for Prevention & Treatment of Ophthalmology and Otolaryngology Diseases with Chinese Medicine, Changsha, Hunan 410208, China) |
| Abstract: |
| Objective To investigate the clinical efficacy of Sanxue Mingmu Tablet combined with Conbercept in the treatment of diabetic macular edema（DME）. Methods A total of 45 DME patients（45 eyes）, who visited the Department of Ophthalmology at the First Hospital of Hunan University of Chinese Medicine from January 2021 to January 2022, were assigned into an experimental group and a control group using a random number table method: the experimental group included 22 patients（22eyes） treated with Sanxue Mingmu Tablet combined with Conbercept, while the control group included 23 patients（23 eyes） treated with Conbercept alone. After treatment, the best corrected visual acuity（BCVA） and central macular thickness（CMT） of the two groups of patients were measured, and the clinical efficacy and incidence of adverse reactions were compared between the two groups. Results Compared with before treatment, the BCVA logMAR values of both groups decreased on 1 day and at 1, 2, and 3 months after treatment（P＜0.05）; further pairwise comparisons revealed that in both groups, the BCVA logMAR values at 1, 2, and 3months after treatment were significantly lower than those at the previous time point（P＜0.05）; compared with the control group, the experimental group showed significantly lower BCVA logMAR values at 1, 2, and 3 months after treatment（P＜0.05）. Compared with before treatment, CMT decreased in both groups at 1, 2, and 3 months after treatment（P＜0.05）; further pairwise comparisons revealed that both groups showed a decrease in CMT at 1, 2, and 3 months after treatment compared to the previous time point（P＜0.05）; compared with the control group, the experimental group showed a decrease in CMT at 1, 2, and 3 months after treatment（P＜0.05）. The total clinical effective rate of the experimental group was higher than that of the control group（P＜0.05）, and no adverse reactions occurred in both groups. Conclusion Both Sanxue Mingmu Tablet and Conbercept can effectively improve the visual acuity and reduce CMT in patients with DME, and the effect of combined use of the two is more significant. |
| Key words: diabetic macular edema Sanxue Mingmu Tablet Conbercept best corrected visual acuity central macular thickness clinical efficacy |
|
二维码（扫一下试试看！） |
|
|
|
|
